Study S000403

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02089256
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 10
Start: 2014-06
Primary completion: 2015-03
Lead sponsor: University of Tartu
Conditions: Healthy
Interventions: DRUG:Liraglutide
Results posted: FALSE

Registered primary outcomes

Change in the glucose-sensitivity of the beta cells [baseline, first dose, after 3-weeks on treatment]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004869	GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers. Heinla K, Diabetes therapy : research, treatment and education of diabetes and related disorders	2023	Randomized trial	PMID 36800161 DOI	cites ClinicalTrials.gov:NCT02089256; registry reference DERIVED:36800161
R0010160	Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect. Sedman T, The Journal of clinical endocrinology and metabolism	2017	Other trial	PMID 28379427 DOI	cites ClinicalTrials.gov:NCT02089256; registry reference DERIVED:28379427
R0016298	Liraglutide Treatment May Affect Renin and Aldosterone Release. Sedman T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme	2017	Other trial	PMID 27300475 DOI	cites ClinicalTrials.gov:NCT02089256; registry reference DERIVED:27300475